Imunexus Therapeutics Limited is an Australian biotechnology company developing next-generation biologic medicines for serious diseases with significant unmet medical needs.
Our research focuses on diseases driven by complex immune and inflammatory processes, where conventional single-target therapies may be insufficient.
The company’s patented imunexin™ technology platform enables the creation of multispecific biologics designed to perform multiple therapeutic functions within a single molecule.
Our lead program, IMX39, is being developed for multiple sclerosis, a chronic neurological disease that causes immune-driven inflammation, nerve damage and progressive disability.
IMX39 is a multispecific biologic designed to target key biological processes involved in multiple sclerosis.
While most current MS therapies focus primarily on suppressing immune activity, IMX39 is designed to intervene earlier in the disease process while also supporting mechanisms associated with nerve repair.
In preclinical studies, IMX39 showed strong disease-modifying activity, improved motor function and evidence of remyelination, the repair of the damaged protective myelin layer around nerve cells.
Learn more about IMX39A modular platform for generating multispecific biologics.
The imunexin™ platform is a patented technology designed to create multispecific biologic therapies by adding additional therapeutic functions to established drug formats such as antibodies, enzymes and cell therapies.
This modular approach converts a traditional single-function medicine into a multispecific therapy capable of addressing multiple biological pathways while preserving the original drug structure.
The platform enables the rapid development of differentiated medicines and the creation of new intellectual property across multiple disease areas.
Explore the platformPrograms spanning neurology, oncology, rare disease and regenerative medicine.
Multiple sclerosis (lead program progressing into human trials)
Small cell lung cancer (unmet medical need)
Gaucher’s disease (rare inherited paediatric disease)
Imunexin ™ enhanced mesenchymal stem cell therapy (partnered with Mesoblast Ltd)
